Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 385.00p 370.00p 400.00p 385.00p 385.00p 385.00p 3,450 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 21.9 260

Eco Animal Health Share Discussion Threads

Showing 226 to 250 of 1050 messages
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
20/10/2011
22:49
Must be news on the way. I am hopeful that imminent FDA aproval is the cause for an impressive rise in a poor market.
maxchampagne
20/10/2011
15:01
We appear to be moving north again!
audigger
10/10/2011
17:21
Well my speculation was wrong. On a bit of a drift at the moment so another opportunity to add. Not sure I understand the last RNS. Is it realy a bit of dilution and director sells or simply re-alignment to a new option scheme? Is this respeonsible for the recent drift? I intend to add but have to decide first which of my rather ill portfolio to sell at a loss to get the cash I need to re-invest here.
audigger
25/8/2011
12:25
Lets hope you are correct. I'm sure patience will be rewarded here at some point, so not particularly worried about timing.
topvest
25/8/2011
09:31
Well its pay-day for me today, so think I will buy some more. I working on the theory (and it is only a theory) that Eco will get the FDA approval before the end of FDA's current fiscal year (Sept 30 2011). The VMAC are next scheduled to meet on Sept 12 so my hope is that this is when FDA approval will be granted. All speculation and wishful thinking!
audigger
22/8/2011
10:59
Last trade shows as 1.72. Can't be right?
audigger
22/8/2011
10:57
Strange that this held-up so well during markt chaos but now the market is a tad blue gain this is sliding. Tempted to add, but waiting to see if they slide a little further.
audigger
09/8/2011
17:19
Back to normal, -14p, I should have waited a little longer before adding!
audigger
09/8/2011
16:18
Very strange share price movements. Was 14p down now back to level for the day. Also trades have vanished. Must be an ADVFN glitch.....will have to check Sp on another website
audigger
09/8/2011
13:08
Well these are suddenly cheaper. Have added albeit not many as ain't got much spare cash at the moment. If these get to around 190, then I'll be selling some other shares to buy more as, market chaos aside, these are looking a very attractive prospect once FDA approval is granted
audigger
25/7/2011
09:03
..... and what about the anti viral potential of Aivlosin.Research is continuing in 3 countries on this possibility and a positive outcome will have a major impact on the value of EAH.£6min without this according to Cenkos.What price with it?????
ltinvestor
24/7/2011
14:09
It's almost inevitable IMO that a takeover bid will occur after Aivlosin's full potential becomes apparent in the coming months .
roverite12
23/7/2011
17:15
Interesting...particularly this bit... The broker pointed out that ECO's business model uses third-party distributors who earn up to 50 per cent margins. If the company was acquired by a multinational animal health business, with its own sales force, then the gross profit contribution that could be achieved would be nearly treble that currently produced by ECO.
topvest
23/7/2011
14:51
PROACTIVE article - dated 4pm 22 JULY Shares in ECO Animal Health Group (LON:EAH) were higher by 6.6 per cent at 235 pence each by 1pm today, after the company said its current financial year had started well and reported a strong increase in profit and revenue for the 12 months to 31 March. ECO, which makes environmentally-friendly drugs for livestock, said it had seen positive trends in many of its key markets. Demand from China, its largest market, is strong and it continues to build a presence there and in other important territories. The firm added that it was optimistic that it would soon receive clearance from the US Food and Drug Administration to begin sales of Aivlosin – its flagship drug that is used to provide control of major respiratory and enteric diseases in both pigs and poultry – in that country. Today's results showed that the group increased its turnover for the year to 31 March by 24.4 per cent to £27.1 million (2010: £21.7 million), while its profit – before non-cash charges such as tax, depreciation and amortisation – improved by more than 16 per cent to £6.4 million. On average margins were slightly lower, restrained by currency movements such as last year's strength of sterling against the US dollar as well as by the regional mix of Aivlosin sales and an aggressive local pricing policy to secure large tender business in Brazil. But sales growth in key markets was strong. China, India and Japan posted growth in excess of 40 per cent, while Latin America and South East Asia saw growth exceeding 25 per cent. Sales from ECO's Chinese subsidiary Zhejiang ECO Biok Animal Health Products were greater by nearly 30 per cent in the local currency (and by close to 35 per cent in sterling). ECO said it believes that China remains the market with the greatest potential for its products and it is continuing to seek further opportunities in the country. After China, the US – a market that represents about one third of global demand for animal health drugs – is the next major market that the company is targeting and it expects to launch there soon. The US FDA is still studying ECO's most-recent dossier submission to allow the firm to obtain its first Aivlosin marketing authorisation for a pig claim, while more work is being carried out so that further claims for Aivlosin in the US can be added in the near future. ECO's Japanese subsidiary, ECOpharma, exceeded expectations during its first full year of trading. Following the earthquake in Japan in March 2011, the business's staff and customers remained safe from danger and business returned to normal quickly, ECO said. Europe was broadly flat during the year, reflecting challenging economic conditions in the region. But the firm added that the UK was a notable exception with ECO's new direct-to-market strategy, together with the launch of Aivlosin for 'bulgy eye' – a respiratory disease of pheasants caused by mycoplasma – being well received, delivering sales growth of more than 40 per cent. Cash generation at ECO continued to be strong during the year, with £8.5 million generated compared with £3.3 million in 2010. The firm said that this was achieved thanks to the ongoing implementation of its aggressive stock and debtor management policies ECO has declared a dividend of three pence per share for the year – an increase of 30 per cent over the 2.3 pence it declared for 2010. "ECO Animal Health Group has delivered another strong set of results for the year ended 31 March 2011 and the current year has started well," said Peter Lawrence, ECO's executive chairman. "Overall, ECO is well positioned with an excellent product range, exciting growth opportunities and potentially very important new products in the development phase. The company is poised to accelerate its growth and continue to deliver value to its shareholders." Cenkos Securities, ECO's house broker, believes the group is close to receiving marketing authorisation for Aivlosin in the US. "This represents a huge opportunity for the group although the timeline (which is outside of ECO's control) has lengthened beyond our original expectations," it said. Cenkos forecasts revenues for the current financial year to 31 March 2012 at £30 million, with adjusted pre-tax profits of £3.1 million (translating to earnings per share of 4.2 pence). The broker pointed out that ECO's business model uses third-party distributors who earn up to 50 per cent margins. If the company was acquired by a multinational animal health business, with its own sales force, then the gross profit contribution that could be achieved would be nearly treble that currently produced by ECO. For this reason, Cenkos believes that ECO could be worth 600 pence per share.
roverite12
22/7/2011
13:39
I think the company were asked to provide FDA with additional information and/or clarify questions they had as ECO refer to thier most recent dossier submission "The Food and Drug Administration (FDA) in America is still studying our most recent dossier submission to allow ECO to obtain its first Aivlosin® marketing authorisation for a pig claim. Concurrently, more work is being carried out so that further claims for Aivlosin® in the USA can be added in the near future. Timelines continue to be extended and, as ever, this is completely out of our control". This is all part of the normal proceedings for a new registration but is unfortunately very time consuming.
audigger
22/7/2011
10:33
Yes, all very positive. Are the FDA the slowest organisation or what!? Patience needed, but expect they will get the approval soon.
topvest
22/7/2011
09:08
I am just looking at my portfolio to see what I can sell in order to increase my already substantial holding!!
ltinvestor
22/7/2011
07:59
And a reasonable 3p divi
audigger
22/7/2011
07:42
Wasn't expecting the results until Monday, looks like they are out early. This is an impressive set of results and interesting that they are taking steps to increase liquidity. Canadian approval is always a good benchmark of what may come from FDA so I truly beleive FDA approval will happen this year. I'm also impressed with their approach to currency movements. Looks like a very well run company. Given that this is positive across the board and that it is likely to be a blue day all round I'm expecting a big (circa 20 p) jump today....
audigger
06/7/2011
20:28
Yes, so am I - could take a few years though. Patience required but should be a good reward eventually.
topvest
06/7/2011
09:19
I agree Topvest that the FDA approval is so material to the company that it will need to be announced once known.We should at least receive an update on progress on the 25th unless, of course, it has been granted prior.I am still confident that a takeout in excess of £5 per share will be achieved and note the activity at Axis Shield today.
ltinvestor
04/7/2011
21:21
Yes, sounds good. The FDA approval would need to be announced once it is known rather than waiting for the results though. Patience required, but no doubt it will be granted at some point.... maybe in a few weeks, months or years!
topvest
04/7/2011
10:27
A bit of news at last and a hint that things are going well. May we finally get news of FDA approval on 25th?
audigger
15/6/2011
15:55
In the meantime, the company has to wait to get full value for its IP. FDA should compensate!
audigger
13/6/2011
07:58
The delay just goes to show how difficult it is to obtain FDA approval for a drug which is already approved and being used in many countries globally.It also shows how valuable this drug will be once approved. I look forward to the day!
ltinvestor
Chat Pages: Latest  18  17  16  15  14  13  12  11  10  9  8  7  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190824 13:25:39